Growth hormone (GH) stimulates lipolysis in mature adipocytes and primary preadipocytes but promotes adipogenesis in preadipocyte cell lines. The lactogenic hormones (prolactin [PRL] and placental lactogen) also stimulate adipogenesis in preadipocyte cell lines but have variable lipolytic and lipogenic effects in mature adipose tissue. We hypothesized that differences in expression of GH receptors (GHR) and PRL receptors (PRLR) during adipocyte development might explain some of the differential effects of the somatogens and lactogens on fat metabolism. To that end, we compared: (a) the expression of GHR and PRLR mRNAs in 3T3-L1 preadipocytes during the course of adipocyte differentiation; (b) the induction of STAT-5 activity by GH and PRL during adipogenesis; and (c) the acute effects of GH and PRL on the suppressors of cytokine signaling (SOCS-1–3 and cytokine-inducible SH2-domain-containing protein [CIS]) and IGF-I. In confluent, undifferentiated 3T3-L1 cells, the levels of GHR mRNA were ∼250-fold higher than the levels of PRLR mRNA. Following induction of adipocyte differentiation the levels of PRLR mRNA rose 90-fold but GHR mRNA increased only 0.8-fold. Expression of both full-length (long) and truncated (short) isoforms of the PRLR increased during differentiation but the long isoform predominated at all time points. Mouse GH (mGH) stimulated increases in STAT-5a and 5b activity in undifferentiated as well as differentiating 3T3-L1 cells; mouse PRL (mPRL) had little or no effect on STAT-5 activity in undifferentiated cells but stimulated increases in STAT-5a and 5b activity in differentiating cells. mGH stimulated increases in SOCS-2 and SOCS-3 mRNAs in undifferentiated cells and SOCS-1–3 and CIS mRNAs in differentiating cells; mPRL induced CIS in differentiating cells but had no effect on SOCS-1–3. mPRL and mGH stimulated increases in IGF-I mRNA in differentiating cells but not in undifferentiated cells; the potency of mGH (3–6-fold increase, p < 0.01) exceeded that of mPRL (40–90% increase, p < 0.05). Our findings reveal disparities in the expression of PRLR and GHR during adipocyte development and differential effects of the hormones on STAT-5, the SOCS proteins, CIS, and IGF-I. These observations suggest that somatogens and lactogens regulate adipocyte development and fat metabolism through distinct but overlapping cellular mechanisms.

Keywords:
Insulin-like growth factor, Suppressors of cytokine signaling, Cytokine-inducible SH2-domain-containing protein, Adipogenesis, Lactogen
1.
Gosteli-Peter MA, Winterhalter KH, Schmid C, Froesch ER, Zapf J: Expression and regulation of IGF-I and IGF binding protein mRNA levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone. Endocrinology 1994;135:2558–2567.
2.
Flint DJ, Binart N, Kopchick J, Kelly P: Effects of growth hormone and prolactin on adipose tissue development and function. Pituitary 2003;6:97–102.
3.
Hansen LH, Madsen B, Teisner B, Nielsen JH, Billestrup N: Characterization of the inhibitory effect of growth hormone on primary preadipocyte differentiation. Mol Endocrinol 1998;12:1140–1149.
4.
Wabitsch M, Braun S, Hauner H, Heinze E, Ilondo MM, Shymko R, DeMeyts P, Teller WM: Mitogenic and antiadipogenic properties of human growth hormone in differentiating human adipocyte precursor cells in primary culture. Pediatr Res 1996;40:450–456.
5.
Yarwood SJ, Sale EM, Sale GJ, Houslay MD, Kilgour E, Anderson NG: Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S2 kinease signaling. J Biol Chem 1999;274:8662–8668.
6.
Shang CA, Waters MJ: Constitutively active signal transducer and activator of transcription 5 can replace the requirement for growth hormone in adipogenesis of 3T3–F442A preadipocytes. Mol Endocrinol 2003;17:2494–2508.
7.
Stewart WC, Baugh JE Jr, Floyd ZE, Stephens JM: STAT5 activators can replace the requirement of FBS in the adipogenesis of 3T3-L1 cells. Biochem Biophys Res Commun 2004;324:355–359.
8.
Nanbu-Wakao R, Fujitani Y, Masuho Y, Muramatu M, Wakao H: Prolactin enhances CCAAT enhancer-binding protein-β and peroxisome proliferator-activated receptor messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells, Mol Endocrinol 2000;14:307–316.
9.
Freemark M, Fleenor D, Driscoll P, Binart N, Kelly P: Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 2001;142:532–537.
10.
Freemark M: Regulation of maternal metabolism by pituitary and placental hormones: roles in fetal development and metabolic programming. Horm Res 2006;65(suppl 3):41–49.
11.
Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H: Identification of functional prolactin receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 2003;88:1804–1808.
12.
Ling C, Hellgren G, Gebre-Medhin M, Dillner K, Wennbo H, Carlsson B, Billig H: Prolactin receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice. Endocrinology 2000;141:3564–3572.
13.
Fielder PJ, Talamantes F: The lipolytic effects of mouse placental lactogen II, mouse prolactin, and mouse growth hormone on adipose tissue from virgin and pregnant mice. Endocrinology 1987;121:493–497.
14.
Iliou JP, Demarne Y: Evolution of the sensitivity of isolated adipocytes of ewes to the lipolytic effects of different stimuli during pregnancy and lactation. Int J Biochem 1987;19:253–258.
15.
Houseknecht KL, Bauman DE, Vernon RG, Byatt JC, Collier RJ: Insulin-like growth factors 1 and 2, somatotropin, prolactin, and placental lactogen are not acute effectors of lipolysis in ruminants. Domest Anim Endocrinol 1996;13:239–249.
16.
Smith PJ, Wised LS, Berkowitz R, Wan C, Rubin CS: IGF-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 1988;263:9402–9408.
17.
Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A: Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques 2004;37:112–119.
18.
Fleenor DE, Freemark M: Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology 2001;142:2805–2810.
19.
Schuler LA, Lu JC, Brockman JL: Prolactin receptor heterogeneity: processing and signalling of the long and short isoforms during development. Biochem Soc Trans 2001;29:52–56.
20.
Woelfle J, Rotwein P: In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab 2004;286:E393–E401.
21.
Wang Y, Jiang H: Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of IGF-I gene expression. J Biol Chem 2005;280:10955–10963.
22.
Tollet-Egnell P, Flores-Morales A, Stavreus-Evers A, Sahlin L, G. Norstedt G: Growth hormone regulation of SOCS-2, SOCS-3 and CIS messenger ribonucleic acid expression in the rat. Endocrinology 1999;140:3693–3704.
23.
Pezet A, Favre H, Kelly PA, Edery M: Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem 1999;274:24497–24502.
24.
Tam SP, Lau P, Djiane J, Hilton DJ, Waters MJ: Tissue-specific induction of SOCS gene expression by PRL. Endocrinology 2001;142:5015–5026.
25.
Dif F, Saunier E, Demeneix B, Kelly PA, Edery M: Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor. Endocrinology 2001;142:5286–5293.
26.
Endo T, Sasaki A, Minoguchi M, Joo A, Yoshimura A: CIS1 interacts with the Y532 of the prolactin receptor and suppresses prolactin-dependent STAT5 activation. J Biochem 2003;133:109–113.
27.
Martens N, Uzan G, Wery M, Hooghe R, Hooghe-Peters EL, Gertler A: Suppressor of cytokine signaling 7 inhibits prolactin, growth hormone, and leptin signaling by interactin with STAT5 or STAT3 and attenuating their nuclear translocation. J Biol Chem 2005;280:13817–13823.
28.
Verdier F, R. Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, Muller O, Mayeux P, Lacombe C, Gisselbrecht S, Chretien S: A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B, Mol Cell Biol 1998;18:5852–5860.
29.
McAveney KM, Gimble JM, Yu-Lee L-Y: Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996;137:5723–5726.
30.
Dupont J, Khan J, Qu B-H, Metzler P, Helman L, LeRoith D: Insulin and IGF-I induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 2001;142:4969–4975.
31.
Iida K, Takahashi Y, Kaji H, Yoshioka S, Murata M, Iguchi G, Okimura Y, Chihara K: Diverse regulation of full-length and truncated GH receptor expression in 3T3-L1 adipocytes. Mol Cell Endocrinol 2003;210:21–29.
32.
Zhou L, Menon RK, Sperling MA: Induction of mRNAs for the growth hormone receptor gene during mouse 3T3-L1 preadipocyte differentiation. Metabolism 1997;46:114–118.
33.
Stephens JM, Morrison RF, Pilch PF: The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. J Biol Chem 1996;271:10441–10444.
34.
Nanbu-Wakao R, Morikawa Y, Matsumura I, Masuho Y, Muramatsu MA, Senba E, Wakao H: Stimulation of 3T3-L1 adipogenesis by signal transducer and activator of transcription 5. Mol Endocrinol 2002;16:1565–1576.
35.
Chen NX, Hausman GJ, Wright JT: Hormonal regulation of IGF binding proteins and IGF-I secretion in porcine stromal-vascular cultures. J Anim Sci 1996;74:2369–2375.
36.
Zhang H, Nohr J, Jensen CH, Petersen RK, Bachmann E, Teisner B, Larsen LK, Mandrup S, Kristiansen K: IGF-I/insulin bypasses Pref-1/FA1-mediated inhibition of adipocyte differentiation. J Biol Chem 2003;278:20906–20914.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.